Pfizer Inc. raised its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost from previous projections that reflects the preference many governments have for the shot over rivals.
The New York-based drugmaker said its sales forecast for the vaccine it developed with partner BioNTech SE reflects expectations to deliver about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and they have begun working with other firms overseas to produce doses.
